Denecimig - Novo Nordisk
Alternative Names: Coagulation factor VIII mimetic antibody - Novo Nordisk; FVIII mimetic antibody - Novo Nordisk; Mim-8; NN 7769; NN0365-3769; NNC0365-3769; NNC0365-3769 ALatest Information Update: 08 May 2026
At a glance
- Originator Novo Nordisk
- Developer Genmab; Novo Nordisk
- Class Antihaemorrhagics; Bispecific antibodies
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Haemophilia A
- Preclinical Haemophilia B
Most Recent Events
- 29 Apr 2026 Efficacy and adverse events data from a phase III trial in Haemophilia A released by Novo Nordisk
- 06 Dec 2025 Efficacy and adverse events data from a phase III trial in Haemophilia A presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
- 06 Dec 2025 Preclinical trials in Haemophilia B in Denmark (SC) before December 2025